NASDAQ:ADVM

Eli Lilly (LLY) Pops on Fresh Deal Spree: MeiraGTx Gene Therapy Tie‑Up, New AI Collaboration, and Leerink Upgrade — Nov. 10, 2025

Eli Lilly agreed to pay $75 million upfront and over $400 million in milestones for global rights to MeiraGTx’s pediatric blindness gene therapy. The company also announced an AI drug discovery partnership with Insilico Medicine, worth over $100 million in potential payments. Leerink Partners upgraded Lilly shares and raised its price target to $1,104, sending the stock up about 5% intraday.

10 November 2025

Artificial Intelligence·NASDAQ:ADVM·NASDAQ:MGTX·NASDAQ:NVDA·NYSE:LLY·Pharmaceuticals·Stock Market

Adverum (ADVM) Stock Skyrockets on News of Lilly’s $12.47/Share Gene Therapy Deal

Eli Lilly said Oct. 24 it will buy Adverum Biotechnologies for $3.56 per share plus a CVR worth up to $8.91, targeting Adverum’s lead gene therapy Ixo-vec for wet AMD. Adverum shares jumped 17% on the news but stayed well below the $12.47 maximum deal value. The agreement includes a $65 million secured loan to fund trials before closing. Adverum had warned its cash would run out by Q4 2025.

24 October 2025

Mergers and Acquisitions·NASDAQ:ADVM·NYSE:LLY·Stock Market

York Space Systems Shares Drop Sharply Amid Valuation Concerns but DCF Model Shows Potential Undervaluation
March 20, 2026, 2:27 PM EDT. York Space Systems (YSS) shares have fallen 47.4% year-to-date amid rising concerns over short-term pressure and sector volatility in satellite technology and defense. The stock declined 11.5% over the past week and nearly 37% over 30 days, reflecting shifting market sentiment. Despite the decline, a Discounted Cash Flow (DCF) analysis estimates an intrinsic value of $33.45 per share, significantly above the current price of $17.68, suggesting the shares may be undervalued by 47.2%. The company reported a free cash flow loss of $20.7 million over the last twelve months but projects growth to $255.7 million by 2035. York Space Systems scores low on valuation metrics, indicating potential risks for investors amid uncertainty in funding and contracts within the space sector.